Eli Lilly & Company (NYSE: LLY) has announced a $450 million investment plan to expand its production capacity at the Research Triangle Park (North Carolina) facilities and thus at least 100 new jobs, The expansion includes additional parenteral filling, device assembly and packaging capacity to meet growing demand for Lilly’s incretin drugs that treat diabetes.
“In 2023, Lilly will focus on finding innovative solutions to meet the growing demand for our medicines,” said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. ,Expanding Your Operations at the North Carolina Research Park This will accelerate the rate at which we can produce drugs to address serious health problems such as diabetes. We are on track to meet our goal of doubling incretin capacity by the end of this year, in November 2022, and this investment is critical to ensuring that even more patients in the future get the medicines they need. “
From 2020 onwards, lily Invested approximately $4 billion in a new manufacturing facility in North Carolina, including $1.7 billion for the development and expansion of this production facility. The company expects to begin initial production this year in preparation for US Food and Drug Administration (FDA) inspections.
Since 2014, Lilly made available to patients and professionals Health care plans to introduce 18 new drugs and potential new treatments in 2023 to improve the lives of people affected by diseases such as diabetes and cancer. This expansion is a significant development for Lilly’s current drug supply as it prepares to bring in its next generation of drugs. Medicines to patients around the world.
The expansion, which will be fully operational by 2027, will create at least 100 new jobs, primarily for manufacturing personnel who will use advanced technology to produce incretin treatments and medical devices.
As lily The company looks to further expand its global manufacturing network to ensure an adequate supply of medicines for everyone, while preparing for an expected surge in potential new drugs to treat diabetes, obesity, Alzheimer’s disease, cancer and autoimmune conditions .
